HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc. (TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback